Completed PHASE4 INTERVENTIONAL 1-arm NCT04914832

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

Sponsor: AstraZeneca

Interventions AZD1222

Updated 6 times since 2021 Last updated: Aug 24, 2023 Started: Aug 30, 2021 Primary completion: Sep 30, 2022 Completion: Sep 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on COVID-19 and Pneumonia, Viral, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jul 2023 — Sep 2023 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Sep 2021 — Jul 2023 [monthly]

Not Yet Recruiting PHASE4

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Shabir Madhi

Data source: University of Witwatersrand, South Africa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mbabane, Eswatini